BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 30312200)

  • 1. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Simons JM; van Nijnatten TJA; van der Pol CC; Luiten EJT; Koppert LB; Smidt ML
    Ann Surg; 2019 Mar; 269(3):432-442. PubMed ID: 30312200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
    van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
    Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
    van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
    Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
    Donker M; Straver ME; Wesseling J; Loo CE; Schot M; Drukker CA; van Tinteren H; Sonke GS; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg; 2015 Feb; 261(2):378-82. PubMed ID: 24743607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB; Donker M; Straver ME; van der Noordaa MEM; Rutgers EJT; Valdés Olmos RA; Vrancken Peeters MJTFD
    Br J Surg; 2017 Aug; 104(9):1188-1196. PubMed ID: 28524246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.
    van Hemert AKE; van Duijnhoven FH; Vrancken Peeters MTFD
    Breast; 2023 Oct; 71():89-95. PubMed ID: 37562108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
    J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
    Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
    Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
    Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
    BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
    El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K
    Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
    Zetterlund LH; Frisell J; Zouzos A; Axelsson R; Hatschek T; de Boniface J; Celebioglu F
    Breast Cancer Res Treat; 2017 May; 163(1):103-110. PubMed ID: 28224384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axillary staging prior to or after neoadjuvant systemic therapy? A single institutional experience.
    Al Mushawah F; Tan MC; Margenthaler JA
    J Surg Oncol; 2010 Oct; 102(5):404-7. PubMed ID: 20082352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
    Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
    Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis.
    Fu JF; Chen HL; Yang J; Yi CH; Zheng S
    PLoS One; 2014; 9(9):e105316. PubMed ID: 25210779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.